EUVIMEDEUVIMED entdecken
Crossref

Utilization of donor‐derived Cell‐Free DNA in pediatric kidney transplant recipients: A single center study

Daniel Ranch iD, Mingwei Fei, Elisabeth Kincade, Kim Piburn, Kelley Hitchman iD, Kelsey Klein iD

Pediatric Transplantation · 2024-02 · 28 (1)

DOI: 10.1111/petr.14582 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pediatric Transplantation, online erschienen am 07.08.2023. Verfasst von Daniel Ranch und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, UT Health San Antonio, San Antonio, Texas, USA. Hauptthemen laut MEDLINE: Kidney Transplantation, Cell-Free Nucleic Acids. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 26 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

High donor‐derived cell‐free DNA (dd‐cfDNA) levels indicate transplant allograft injury and can identify graft rejection in kidney transplant recipients. Here, we evaluated the use of dd‐cfDNA in pediatric kidney transplant rejection monitoring and treatment.

Methods

Forty‐two pediatric kidney transplant patients were enrolled between February 2020 and August 2021. Dd‐cfDNA was tested before and after biopsy/rejection treatment. There was a total of 61 allograft biopsies (44 for‐cause, 17 surveillance).

Results

Graft rejection was found in 35/61 biopsies. Rejection was more common in basiliximab induction compared to rATG (77.1% vs. 22.9%, p = .0121). Median dd‐cfDNA was higher in those with rejection (1.2% [0.34–3.12] vs. 0.24% [0.08–0.78], p < .0001). Dd‐cfDNA was highest in biopsies with AMR and mixed AMR/TCMR. In addition, dd‐cfDNA in basiliximab induction was higher compared to rATG (0.92% [0.27–1.8] vs. 0.26% [0.08–2], p = .0437). Median change in dd‐cfDNA after rejection treatment was −0.57% (−1.67 to 0.05). Median time to dd‐cfDNA

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Kidney TransplantationCell-Free Nucleic AcidsHumansChildBasiliximabTissue DonorsTransplantation, HomologousGraft RejectionTransplant Recipients

Stichwörter der Autor:innen

acute rejectionanti-HLA antibodyantibody mediated rejectionpediatric kidney transplantation

Substanzen

BasiliximabCell-Free Nucleic Acids

Autor:innen und Institutionen

  • Department of Pediatrics, UT Health San Antonio, San Antonio, Texas, USA.
  • Biostatistics Department, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
  • University Health Transplant Institute, San Antonio, Texas, USA.
  • Pharmacotherapy Division, College of Pharmacy, The University of Texas at Austin, Austin, Texas, USA.
  • Department of Pathology and Laboratory Medicine, UT Health San Antonio, San Antonio, Texas, USA.

ORCID-Profile: Daniel Ranch, Kelley Hitchman, Kelsey Klein

Zitieren

APA

Ranch, D., Fei, M., Kincade, E., Piburn, K., Hitchman, K., & Klein, K. (2024). Utilization of donor‐derived Cell‐Free DNA in pediatric kidney transplant recipients: A single center study. Pediatric Transplantation, 28(1). https://doi.org/10.1111/petr.14582

Vancouver

Ranch D, Fei M, Kincade E, Piburn K, Hitchman K, Klein K. Utilization of donor‐derived Cell‐Free DNA in pediatric kidney transplant recipients: A single center study. Pediatric Transplantation. 2024;28(1). doi:10.1111/petr.14582

BibTeX
@article{Ranch2024,
  author = {Ranch, Daniel and Fei, Mingwei and Kincade, Elisabeth and Piburn, Kim and Hitchman, Kelley and Klein, Kelsey},
  title = {Utilization of donor‐derived Cell‐Free DNA in pediatric kidney transplant recipients: A single center study},
  journal = {Pediatric Transplantation},
  year = {2024},
  volume = {28},
  number = {1},
  doi = {10.1111/petr.14582}
}
Kostenlos starten →